MTFR1L

Across TCGA pan-cancer cohorts, MTFR1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTFR1L data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTFR1L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MTFR1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where MTFR1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.601	0.377	.006	21	view →
CCRCC	OS	Quartile	All	0.956	0.683	.002	19	view →
HNSC	DFS	Quartile	All	0.872	0.974	.017	17	view →
GBM	DFS	Tertile	All	0.964	0.612	<.001	13	view →
LUAD	OS	Median	All	0.967	0.768	.017	7	view →
LSCC	DFS	Tertile	All	0.440	1.000	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTFR1L–PDAC (OS)

Open the PDAC breakdown →